{
  "id": "54fc98f16ad7dcbc12000003",
  "type": "summary",
  "question": "Describe the mechanism of action of drisapersen",
  "ideal_answer": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. It has potential for treatment of Duchenne muscular dystrophy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25209738",
    "http://www.ncbi.nlm.nih.gov/pubmed/24292388",
    "http://www.ncbi.nlm.nih.gov/pubmed/24620745",
    "http://www.ncbi.nlm.nih.gov/pubmed/23995279",
    "http://www.ncbi.nlm.nih.gov/pubmed/24321374",
    "http://www.ncbi.nlm.nih.gov/pubmed/24229740"
  ],
  "snippets": [
    {
      "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UNLABELLED: Chronic administration of drisapersen, a 2'-OMe phosphorothioate antisense oligonucleotide (AON) to mice and monkeys resulted in renal tubular accumulation, with secondary tubular degeneration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fast forward 25 years, and two phase 2b/3 trials have been carried out with agents designed to induce de novo dystrophin production in DMD patient's muscle; ataluren (stop codon read through) with 174 patients, and drisapersen (exon skipping) with 186 patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24229740",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}